tavilermide
Tavilermide is a selective, cyclic tripeptide partial agonist of TrkA. This class of drugs is sometimes referred to as nerve growth factor (NGF) mimetics. Tavilermide was first synthesized by Burgess and co-workers at Texas A&M University with the intention of producing TrkA agonists. It is under development by Mimetogen Pharmaceuticals as an ophthalmic solution for the treatment of dry eyes, and is in phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye disease. Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing. — Wikipedia
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2010 (NCT01257607)
Timeline
Indications
Mechanism of action
- Nerve growth factor receptor Trk-APARTIAL AGONIST
NTRK1 partial agonist
Chemistry & pharmacology
SMILES
NCCCC[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)c2cc([N+](=O)[O-])ccc2OCC[C@@H](C(=O)NCC(=O)O)NC1=O- Mol. weight
- 580.55 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTavilermide ↗
- ChEMBLCHEMBL3544981 ↗
Also known as
- mim-d3
- mim-d3
- tavilermide
- tavilermide
- tavilermide
- tavilermide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05848128 | Phase 3 | Jun 28, 2023 | Mimetogen Pharmaceuticals USA, Inc. |
| NCT03925727 | Phase 3 | Mar 28, 2019 | Mimetogen Pharmaceuticals USA, Inc. |
| NCT02665234 | Phase 3 | Jan 1, 2016 | Mimetogen Pharmaceuticals USA, Inc. |
| NCT02634853 | Phase 3 | Dec 1, 2015 | Mimetogen Pharmaceuticals USA, Inc. |
| NCT01960010 | Phase 3 | Oct 1, 2013 | Mimetogen Pharmaceuticals USA, Inc. |
| NCT01257607 | Phase 2 | Nov 1, 2010 | Andover Eye Associates, Central Maine Eye Care, Mimetogen Pharmaceuticals USA, Inc. |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mimetogen Pharmaceuticals USA, Inc. | For profit | 6 | 6 | 2 | 2010 |
| Andover Eye Associates | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Central Maine Eye Care | Academic/Hospital | 1 | 0 | 1 | 2010 |